Skip to content

The Randomized Controlled Clinical Study on Combined Acupuncture and Medication for the Treatment of Peptic Ulcers

The Randomized Controlled Clinical Study on Combined Acupuncture and Medication for the Treatment of Peptic Ulcers

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002489
Enrollment
Unknown
Registered
2025-12-24
Start date
2025-12-20
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic Ulcer

Interventions

Treatment Group:Zusanli (ST36), Zhongwan (CV12), Neiguan (PC6), Sanyinjiao (SP6). Auxiliary points: For Liver Qi invading stomach syndrome, and Taichong (LR3)
for Stomach obstruction syndrome, and Xuehai (SP10)
for Stomach Yin deficiency syndrome, and Taixi (KI3)
for Spleen and Stomach cold deficiency syndrome, and Guanyuan (CV4). Method of operation: After inserting the filiform needle, perform needling until deqi is obtained. Retain the needle for 30 minutes
Control Group:The sham acupuncture group selected 4 non-acupoints and 4 auxiliary points, using blunted placebo needles for non-meridian, non-acupoint sham acupuncture. During the procedure, the needl

Sponsors

College of Acupuncture and Tuina,Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria (1) Meets the diagnostic criteria of this study; (2) Age =18, =75 years old, gender; (3) Patients willing to cooperate with the treatment methods specified in this study; (4) Abdominal pain/distension VAS score =3; (5) Signed informed consent. Note: Patients who meet all of the above five criteria may be included in this study.

Exclusion criteria

Exclusion criteria: Exclusion Criteria (1) Upper gastrointestinal endoscopy showing perforation of peptic ulcers or malignant tumors; (2) Clinically significant impairment of liver or kidney function (alanine aminotransferase, aspartate aminotransferase greater than 1.5 times the upper limit of normal, serum creatinine greater than the upper limit of normal); (3) Severe cardiovascular, respiratory, endocrine, or central nervous system diseases; (4) History of mental illness; (5) Tendency to bleed or severe skin infections; (6) Pregnant or breastfeeding women; (7) History of allergy to any drugs used in this study. Note: Patients who meet any of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
Effective response rate at the week-6 of treatment;

Secondary

MeasureTime frame
Severity of PU-related abdominal pain;Quality of Life in PU Patients;Self-Rating Anxiety Scale (SAS) Score;Self-Rating Depression Scale (SDS) Score;The number of adverse reactions to Western medicine;Hp negative conversion rate;

Countries

China

Contacts

Public ContactLi Ying

College of Acupuncture and Tuina,Chengdu University of Traditional Chinese Medicine

liying@cdutcm.edu.cn+86 13708095607

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026